Core Viewpoint - The article discusses the challenges faced by patients with liver cancer and highlights the innovative Y-90 resin microsphere selective internal radiation therapy as a promising treatment option that can improve patient outcomes and potentially allow for curative surgery [2][9]. Group 1: Patient Experiences - Zhou Wei was diagnosed with colorectal cancer liver metastasis, with a significant tumor size of approximately 6.9 cm x 7.6 cm, and faced severe pain and deterioration after chemotherapy [1]. - Yu Chengyi, diagnosed with primary liver cancer, experienced ineffective chemotherapy and significant side effects, leading to a rejection of further treatment [1]. - Both patients and their families expressed a sense of urgency in seeking effective treatment options to prolong life and improve quality of life [7][8]. Group 2: Treatment Options - Traditional therapies often have significant side effects and limited effectiveness for larger tumors, with only 20% to 30% of liver cancer patients eligible for surgical resection [3][9]. - Y-90 therapy is a precise treatment method that delivers radiation directly to the tumor's blood supply, minimizing damage to surrounding healthy liver tissue [6][9]. - The treatment has shown promise in converting initially unresectable tumors into operable ones, providing hope for patients with advanced liver cancer [6][9]. Group 3: Clinical Recognition and Guidelines - Y-90 therapy has been recognized in international clinical guidelines as a treatment for primary liver cancer and colorectal cancer liver metastases, with endorsements from various medical organizations [10]. - In China, the therapy has been included in national health guidelines and is increasingly covered by insurance, improving accessibility for patients [11]. Group 4: Future Outlook - The article emphasizes the need for increased awareness and training among medical professionals regarding Y-90 therapy to enhance its availability and effectiveness for more patients [11]. - The positive outcomes observed in patients who underwent Y-90 therapy suggest a shift in the treatment landscape for liver cancer, potentially leading to better survival rates and quality of life [12].